2-(5-(羟基甲基)吡啶-2-基)苯甲腈 | 145733-56-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-(5-(羟基甲基)吡啶-2-基)苯甲腈
• 英文名称: 2-<5-(hydroxymethyl)pyridin-2-yl>benzonitrile
• 英文别名: 2-(5-(hydroxymethyl)pyridin-2-yl)benzonitrile；2-[5-(hydroxymethyl)pyridin-2-yl]benzonitrile
• CAS: 145733-56-8
• 化学式: C₁₃H₁₀N₂O
• 分子量: 210.235
• InChiKey: WOPFMBVSHKMGDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  56.9
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(5-(羟基甲基)吡啶-2-基)苯甲腈 在 zinc(II) chloride 氯化亚砜 作用下， 以 1,4-二氧六环 为溶剂， 以4.30 g (92%)的产率得到2-<5-(chloromethyl)pyridin-2-yl>benzonitrile
  参考文献：
  名称：

  Substituted pyridopyrimidines useful as antgiotensin II antagonists

  摘要：

  本发明涉及一般式I的吡咯基、吡啶基、氮杂七元环和氮杂环丙嘧啶类化合物，对治疗高血压和充血性心力衰竭有用，还涉及制药组合物及其生产方法。

  公开号：

  US05149699A1
• 作为产物：
  描述：

  6-溴烟酸 在 copper(l) iodide 、 正丁基锂 、 bis(triphenylphosphine)palladium(II)-chloride 、 硼烷 、 三丁基氯化锡 、 四丁基氟化铵 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.0h， 生成 2-(5-(羟基甲基)吡啶-2-基)苯甲腈
  参考文献：
  名称：

  Pyrido[2,3-d]pyrimidine Angiotensin II Antagonists

  摘要：

  A series of pyrido[2,3-d]pyrimidine angiotensin II (A II) antagonists was synthesized and tested for antagonism of A II. Compounds with a biphenylyltetrazole pharmacophore and small alkyl groups at the 2- and ii-positions Of the pyridopyrimidine ring were found to be the most potent in an AT(1) receptor binding assay and in blocking the A II presser response in anesthetized, ganglion-blocked A II-infused rats. 5,8-Dihydro-2,4-dimethyl-8-[(2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl)methyl] pyrido[2,3-d]pyrimidin-7(6H)-one (4a) was one of the more potent compounds in the binding assay and was the most efficacious compound in the A II-infused rat model. Further study of 4a;in Goldblatt (2K-1C) rats showed the compound to have oral bioavailability and to be an efficacious and potent compound in a high renin form of hypertension.

  DOI：

  10.1021/jm00030a013

文献信息

• Substituted benzimidazoles and quinazolines as antihypertensives
  申请人：American Home Products Corporation

  公开号：US05283242A1

  公开（公告）日：1994-02-01

  There are disclosed compounds of the formula ##STR1## wherein R.sup.1 is ##STR2## R.sup.2 is ##STR3## wherein X is ##STR4## wherein R.sup.5 is hydrogen, alkyl of 1-6 carbon atoms, benzyl, triphenylmethyl, or Sn(alkyl of 1-6 carbon atoms).sub.3 ; n is 1 to 3; Y is ##STR5## wherein R.sup.3 is hydrogen, perfluoro alkyl of 1-6 carbon atoms, trifluoromethylalkyl of 1-6 carbon atoms, or alkyl of 1-6 carbon atoms; and R.sup.4 is hydrogen or alkyl of 1-6 carbon atoms; with the proviso that when R.sup.1 is ##STR6## then R.sup.2 cannot be ##STR7## wherein X is as defined above; and the pharmaceutically acceptable salts thereof, which by virtue of their ability to antagonize angiotensin II are useful for the treatment of hypertension and congestive heart-failure.

  披露了公式化合物，其中R1是，R2是，其中X是，其中R5是氢，碳原子数为1-6的烷基，苄基，三苯甲基，或Sn(碳原子数为1-6的烷基)3；n为1至3；Y是，其中R3是氢，碳原子数为1-6的全氟烷基，碳原子数为1-6的三氟甲基烷基，或碳原子数为1-6的烷基；R4是氢或碳原子数为1-6的烷基；当R1是时，R2不能是，其中X如上定义；以及药用可接受的盐，它们通过拮抗血管紧张素II的能力，可用于治疗高血压和充血性心力衰竭。
• Rhodium(<scp>iii</scp>)-catalyzed aromatic C–H cyanation with dimethylmalononitrile as a cyanating agent
  作者：He Li、Sheng Zhang、Xiaoqiang Yu、Xiujuan Feng、Yoshinori Yamamoto、Ming Bao

  DOI：10.1039/c8cc08930b

  日期：——

  A rhodium-catalyzed aromatic C–H bond direct cyanation with safe, bench-stable, and commercially available dimethylmalononitrile as the cyanating agent has been successfully developed by using copper oxide as a promotor. Pyridine, quinoline, pyrimidine and pyrazole were used as the directing group in this type of C–H bond direct cyanation reaction.

  通过使用氧化铜作为促进剂，成功开发出了铑催化的芳香族CH键直接氰化，安全，稳定和可商购的二甲基丙二腈作为氰化剂。吡啶，喹啉，嘧啶和吡唑被用作这种C–H键直接氰化反应的导向基团。
• Substituted pyridopyrimidines useful as antgiotensin II antagonists
  申请人：American Home Products Corporation

  公开号：US05149699A1

  公开（公告）日：1992-09-22

  This invention relates to pyrrolo-, pyrido-, azepino-, and azocinopyrimidines of the general formula I ##STR1## useful for treating hypertension and congestive heart failure, to pharmaceutical compositions, and to methods for production thereof.

  本发明涉及一般式I的吡咯基、吡啶基、氮杂七元环和氮杂环丙嘧啶类化合物，对治疗高血压和充血性心力衰竭有用，还涉及制药组合物及其生产方法。
• Substituted pyrrolopyrimidines, azepinopyrimidines and pyridopyrimidines
  申请人：American Home Products Corporation

  公开号：US05256654A1

  公开（公告）日：1993-10-26

  This invention relates to pyrrolo-, pyrido-, azepino-, and azocinopyrimidines of the general formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently H, lower alkyl containing 1 to 6 carbon atoms, or perfluoroalkyl containing 1 to 6 carbon atoms; R.sup.5 is H or when n is 1 R.sup.5 taken together with R.sup.3 comprises a double bond; n is 0 to 1; p is 0 to 2; m is 0 to 3; Ar.sup.1 is ##STR2## wherein W is H, lower alkyl containing 1 to 6 carbon atoms, halogen, hydroxy, or lower alkoxy containing 1 to 6 carbon atoms; Ar.sup.2 is ##STR3## wherein X is ##STR4## wherein R.sup.6 is H, tert-butyl, tri-n-butylstannyl, or triphenylmethyl; and the pharmaceutically acceptable salts thereof which by virtue of their ability to antagonize angiotensin II are useful for the treatment of hypertension, congestive heart failure, and restenosis. The compounds are also useful for reducing lipid levels in the blood plasma and are thus useful for treating hyperlipidemia and hypercholesterolemia. Also disclosed are processes for the production of said compounds and pharmaceutical compositions containing said compounds.

  这项发明涉及一般式I的吡咯烯、吡啶烯、氮杂七元环和氮杂七元杂环嘧啶类化合物，其中R.sup.1、R.sup.2、R.sup.3和R.sup.4分别独立地为H、含有1至6个碳原子的较低烷基，或含有1至6个碳原子的全氟烷基；R.sup.5为H，当n为1时，R.sup.5与R.sup.3一起构成双键；n为0至1；p为0至2；m为0至3；Ar.sup.1为##STR2##其中W为H、含有1至6个碳原子的较低烷基、卤素、羟基或含有1至6个碳原子的较低烷氧基；Ar.sup.2为##STR3##其中X为##STR4##其中R.sup.6为H、叔丁基、三正丁基锡基或三苯甲基；以及它们的药用可接受盐，由于它们具有拮抗血管紧张素II的能力，因此可用于治疗高血压、充血性心力衰竭和再狭窄。这些化合物还可用于降低血浆中的脂质水平，因此可用于治疗高脂血症和高胆固醇血症。还公开了生产这些化合物的方法和含有这些化合物的药物组合物。
• Substituted pyrrolopyrimidines and pyridopyrimidines useful as
  申请人：American Home Products Corporation

  公开号：US05498776A1

  公开（公告）日：1996-03-12

  This invention relates to pyrrolo-, pyrido-, azepino-, and azocinopyrimidines of the general formula I ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently H, lower alkyl containing 1 to 6 carbon atoms, or perfluoroalkyl containing 1 to 6 carbon atoms; R.sup.5 is H or, when n is 1, R.sup.5 taken together with R.sup.3 comprises a double bond, n is 0 or 1, p is 0 to 2, m is 0 to 3; Ar.sup.1 is ##STR2## wherein W is H, lower alkyl containing 1 to 6 carbon atoms, halogen, hydroxy, or lower alkoxy containing 1 to 6 carbon atoms; and Ar.sup.2 is ##STR3## wherein X is ##STR4## wherein R.sup.6 is H, tert-butyl, tri-n-butylstannyl, or triphenylmethyl; and the pharmaceutically acceptable salts thereof, which compounds are useful in the treatment of hypertension and congestive heart failure.

  本发明涉及一般式I的吡咯烷、吡啶烷、氮杂环庚烷和氮杂环壬烷基嘧啶类化合物，其中R1、R2、R3和R4分别独立地为H、含有1至6个碳原子的低碳烷基或含有1至6个碳原子的全氟烷基；R5为H或当n为1时，R5与R3结合成双键；n为0或1；p为0至2；m为0至3；Ar1为##STR2##其中W为H、含有1至6个碳原子的低碳烷基、卤素、羟基或含有1至6个碳原子的低碳基氧基；Ar2为##STR3##其中X为##STR4##其中R6为H、叔丁基、三正丁基锡基或三苯基甲基；以及其药学上可接受的盐，这些化合物在治疗高血压和充血性心力衰竭方面有用。